Ontology highlight
ABSTRACT: Background
Infusion of mesenchymal stromal cells (MSCs) has been proposed as immune-modulatory therapy in solid organ transplantation. The use of allogenic MSCs could improve standardization and allow for direct availability of the product.Method
The nonrandomized phase Ib Neptune clinical trial provided safety and feasibility data on the use of allogenic bone-marrow-derived MSCs, infused in 10 patients at week 25 and 26 post kidney transplantation. Here, we performed detailed analysis on the peripheral blood immune cell composition of these patients up to 52 weeks post transplantation. We used a 40 marker antibody panel with mass cytometry to assess potential effects of MSC therapy on the immune system.Results
We showed minor changes in major immune lineages at wee
SUBMITTER: Hendriks SH
PROVIDER: S-EPMC11500071 | biostudies-literature | 2024
REPOSITORIES: biostudies-literature